Pfizer Inc. (NYSE: PFE) beats adjusted Non-GAAP EPS consensus of approx. $0.68 per share in Q2 2026 earnings (4 August 2026, pre-market, confirmed by Pfizer press release)
Hit
✦ AI-generated prediction
Published on 23. July 2026
·
Predicted for 4. August 2026
·
Based on: Historical Cycle
Pfizer reports Q2 2026 results on August 4, 2026, pre-market. Analyst consensus is approximately $0.68 adjusted Non-GAAP EPS (TipRanks, as of July 2026). Pfizer confirmed FY2026 guidance at Q1 results (April 2026) and beat Q1 estimates. Growth drivers: oncology pipeline (Eliquis, Vyndaqel, Padcev), normalized RSV vaccine demand, and royalties. Headwinds: Paxlovid revenues continue normalizing, and generic competition in older products weighs on gross margin. Historical beat rate: approximately 70% over the last 12 quarters. No Polymarket market available.
Data basis for this prediction
- PFE Q2 2026 Earnings Date: 4. August 2026, vor Börseneröffnung (TipRanks, Stand 23.07.2026)
- PFE Analystenkon sens Q2 2026 EPS: ~0,68 USD Non-GAAP (TipRanks, Stand Juli 2026)
- PFE Q1 2026 bereinigtes EPS: 0,70 USD (beat 0,63 USD Konsens; Pfizer Pressemitteilung, 30.04.2026)
- Pfizer FY2026 EPS Guidance: 2,80–3,00 USD bereinigt (Pfizer Investor Relations, 30.04.2026)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Hit
Pfizer meldete am 4. August 2026 vor Börseneröffnung ein bereinigtes Non-GAAP-EPS von 0,77 USD – damit wurde der Konsens von ca. 0,68 USD um 0,09 USD (≈ 13 %) übertroffen. Zusätzlich übertraf Pfizer auch beim Umsatz (15,03 Mrd. USD ggü. erwartetem Konsens von ca. 14,42 Mrd. USD) und hob den Mittelpunkt der Jahresumsatzguidance an (neu: 60,5–62,5 Mrd. USD). Quellen: Pfizer Q2-2026-Pressemitteilung (BusinessWire / Pfizer IR, 04.08.2026), CNBC, TechTimes, QZ.com.
📈 Economy
✦ AI
The S&P 500 dropped 4.36% on 5 November 2026 to 7,353.73 — its steepest one-day fall since April 2025 — triggered by an AI-chip selloff that wiped out the post-midterm rally (4 November: +1.72% to 7,698.80). Closing above 7,500 by 13 November requires a +2.0% recovery over 6 trading sessions. Goldman Sachs, Morgan Stanley and JPMorgan maintain year-end targets of 7,400–8,100; S&P 500 EPS growth consensus for 2026 stands at +14% YoY. Downside risks: elevated Treasury yields, persistent AI capex uncertainty. No specific Polymarket/Kalshi market found for this level.
📈 Economy
✦ AI
The BLS releases October 2026 CPI on November 10, 2026 at 8:30 AM ET. Nowflation forecasts 3.82 percent YoY; the Cleveland Fed nowcasting model forecasts 3.74 percent — both clearly above the 3.7 percent threshold. The September 2026 prior reading was exactly 3.7 percent. Rising energy prices (Strait of Hormuz effectively closed since mid-October) and stable core inflation support a further uptick. An existing open platform prediction covers CPI >3.5%; this forecast raises the bar by 20 basis points. A miss would primarily require unexpected weakness in the energy component or food prices.
📈 Economy
✦ AI
Gold (XAU/USD) rose to $4,134.83 on 5 November 2026 — driven by the Democratic midterm sweep (higher fiscal spending expected) and persistent inflation pressure. Kalshi's Dec 31 settlement market shows ~32% probability for a close above $4,400 and ~43% for above $4,300. Reaching the $4,400 year-end target would require a further ~6.4% gain. Supporting factors: fiscal expansion, geopolitical risks, structurally high central bank demand; UBS forecasts $4,800, JPMorgan $6,000 at year-end. Headwind: hawkish Fed stance (Polymarket: 72.5% for a December rate hike to 4.00–4.25%). Prediction anchors on Kalshi's ~32% for >$4,400.